
LL-37 Peptide for Sale
Published by Peptara Labs · Updated · How we research and check our pages
Human Antimicrobial Peptide, Studied in Labs
LL-37 peptide from Peptara Labs (peptaralabs.io) is a 5mg research vial of the human cathelicidin, the only antimicrobial peptide of its family made in the human body. A vial costs $66 USD, the LL-37 Black Friday price: 45% off the regular $120. Its batch certificate of analysis is pending, so no purity figure is claimed yet. On pre-order: Ships as soon as stock arrives. Arrival follows transit. It is sold for research use only.
Black Friday price, 45% off, ends November 30
Flat $35 tracked shipping5mg per vial
Ships as soon as stock arrives
$66 USD
Was $120
Add 2 more, unlock 50%
Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Shipping, delivery and certificate status
- Shipping
- Flat $35, tracked worldwide to supported markets
- Delivery
- Ships as soon as stock arrives · After dispatch: 5 to 10 business days
- Included
- Vial · Batch certificate pending · Order support on WhatsApp
Buyer facts
What comes with an LL-37 research order?
The order includes one sealed 5mg vial of lyophilized LL-37. The batch certificate is pending. The table lists the current price and shipping terms. The scientific references describe the molecule, but they do not verify the contents of this batch.
| Detail | Peptara Labs LL-37 (5mg) | Where to check it |
|---|---|---|
| Vial | 5mg of lyophilized LL-37 powder in one sealed vial | Catalog and order summary |
| Price | $66 USD, the LL-37 Black Friday price: 45% off the regular $120 | The order panel above |
| Availability | Pre-order. Ships as soon as stock arrives. Arrival follows transit. | The order panel above |
| Certificate | Batch certificate pending. No purity figure is claimed yet. | Certificates of analysis |
| Delivery after dispatch | Ships as soon as stock arrives · After dispatch: 5 to 10 business days | Order summary and shipping details |
| Status | Laboratory research only | Research and safety record below |
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Share or cite this page
Before you buy
What should be checked before buying LL-37?
Identity and purity answer different questions. A mass test checks whether the sample matches LL-37. HPLC checks the share of the sample represented by the measured peptide. A high purity figure alone cannot establish the right sequence.
- LL-37 has 37 amino acids and a reference molecular weight near 4,493 Da. A certificate should identify the sample and the method that measured it.
- The salt form should be named. Acetate and trifluoroacetate labels appear in reagent catalogs, and the form affects how the mass is described.
- Scrambled and citrullinated variants are separate laboratory materials. A certificate should name the sequence being supplied rather than use LL-37 as a loose family label.
- The certificate should belong to the supplied batch. This page claims no purity or measured identity while the certificate remains pending.
The peptide purity guide explains supplier checks. The certificates page lists documents that have been published and marks pending records.
Sources: UniProt P49913, checked October 7, 2026; PubChem CID 16198951, checked October 7, 2026.
The short answer
What is LL-37?
LL-37 is the only human member of the cathelicidin peptide family. The CAMP gene makes its larger precursor, hCAP18. Enzymes release the 37 amino acid segment from that protein. Neutrophils, a type of white blood cell, and epithelial cells lining body surfaces make the precursor.
Its name describes its sequence: the first two amino acids are leucines, written LL, and its length is 37 amino acids. The peptide has a positive charge and can form a helix with water-facing and lipid-facing sides. Those features help explain its behavior next to cell membranes.
| Property | Reference identity |
|---|---|
| Class | The only human cathelicidin |
| Length | 37 amino acids |
| Precursor | hCAP18, encoded by CAMP |
| Charge | About +6 at normal body pH |
| Structure | A helix with water-facing and lipid-facing sides |
| Main sources | Neutrophils and epithelial cells |
| Sequence | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
| Formula | C205H340N60O53 |
| Molecular weight | About 4,493 Da |
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248); Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440); UniProt P49913, checked October 7, 2026; PubChem CID 16198951, checked October 7, 2026.
The Science
How LL-37 works in research models
LL-37 has membrane activity and immune-signaling activity. Laboratory tests examined these separately, because a microbial membrane, an immune cell and a skin sample can respond differently to the same peptide. Salt and serum also change the behavior seen in simple culture tests.
How does LL-37 work?
Its positive charge draws it toward negatively charged microbial surfaces. In bacterial tests, it disrupted membranes and bound lipopolysaccharide, usually shortened to LPS. The bacterial species and the salt content of the test medium affected activity.
What does LL-37 do besides kill microbes?
Cell tests found that LL-37 drew neutrophils, monocytes and T cells toward it through FPRL1, also called FPR2. That is a movement signal for immune cells, measured in laboratory conditions.
What does vitamin D have to do with LL-37?
The CAMP gene has a vitamin D response element. The active form of vitamin D switched on this gene in cell studies. Researchers found the same gene feature in primates but not mice, which matters when comparing models.
Why context matters
Serum components can blunt LL-37 activity in laboratory tests. Reviews also record damage to host cells as concentration rises. A result from a simple test dish does not establish how the peptide behaves in people.
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530).
Research areas
Common research areas
Antimicrobial and biofilm models
Laboratory research examines microbial growth, membrane contact and communities of microbes called biofilms. These are controlled models whose conditions affect the observations.
Immune-cell signaling
Researchers track immune-cell movement and receptor signals. These studies ask how a host-defense peptide links membrane activity to immune responses.
Skin inflammation research
Rosacea work found altered cathelicidin levels and fragments. Psoriasis research described LL-37 as a T-cell autoantigen, a molecule recognized by the immune system. These are disease associations.
Wound research
Two human trials studied an LL-37 product in venous leg ulcers. The larger trial found no significant healing difference across the whole study group. Neither trial verifies this research vial.
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253).
Comparison
How does LL-37 compare with thymosin alpha-1 and KPV?
These peptides share research topics, but they have different origins and evidence records. A name in an immune-research list does not establish that the compounds work alike.
| Peptide | Identity and research | Human evidence and status |
|---|---|---|
| LL-37 | Human cathelicidin; microbial membranes and immune-cell signaling | Two small wound trials; no medicine approval |
| Thymosin alpha-1 | A separate immune-signaling peptide | Its own page sets out the clinical evidence and country-specific regulator status |
| KPV | The Lys-Pro-Val fragment of alpha-MSH; inflammatory signaling research | Its own page separates cell and mouse findings from the absent human record |
ARA-290, an EPO-derived peptide studied in small nerve trials, is on the ARA-290 peptide page.
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.
Evidence
What did the LL-37 studies measure?
The record includes laboratory mechanisms, skin-disease associations and two human wound trials. Keeping those study types separate makes the findings easier to read. The human trials studied their own LL-37 products, rather than Peptara Labs' pending batch.
1998: microbial membranes
Model: Bacteria in laboratory cultures.
Reported: The authors measured activity against many bacteria. Some organisms resisted LL-37 in salty media. Tests also found E. coli membrane disruption and binding to LPS, a component of bacterial surfaces.
2000: immune signaling
Model: Human neutrophils, monocytes and T cells in laboratory tests.
Reported: Immune cells moved toward LL-37 through FPRL1. The receptor is also called FPR2. This mapped a signaling action beyond direct contact with microbial membranes.
2005: the CAMP gene
Model: Gene and cell studies.
Reported: The active form of vitamin D switched on CAMP through a vitamin D response element. The same gene feature appeared in primate genomes but not mouse genomes.
2007 and 2014: skin associations
Model: Rosacea skin samples and psoriasis immune research.
Reported: The rosacea paper recorded high cathelicidin levels and different fragments. The psoriasis paper described LL-37 as a T-cell autoantigen. These papers examined disease biology.
2014: safety in a small trial
Model: 34 people with hard-to-heal venous leg ulcers, compared with placebo.
Reported: The first human trial mainly examined safety and recorded no safety concerns. Its small population limits what that observation can establish.
2021: the larger wound trial
Model: 148 people with venous leg ulcers in the HEAL LL-37 phase IIb trial.
Reported: The study found no significant healing difference versus placebo across the whole group. A finding in a subgroup with large wounds called for a new study. The developer called the studied product ropocamptide.
The whole-group result of the 2021 trial comes before its subgroup finding. A subgroup can suggest another research question, but it cannot replace the main comparison. Likewise, a small trial without recorded safety concerns cannot establish safety over longer periods.
Sources: Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253).
What is not known
What is not known about LL-37?
The papers cited here give no validated human half-life for LL-37. Half-life means the time for its measured level to fall by half. Serum binding and other interactions also affect activity, so laboratory strength is not a substitute for a study of how it moves through the body.
The side-effect record is incomplete. Reviews report host-cell membrane damage at higher concentrations. The two wound trials were small, and their safety observations cannot settle questions about other settings or longer exposure.
The FDA states concerns about possible immune reactions, peptide impurities and how the material is characterized. It also lists nonclinical signals involving male reproduction and tumor growth in some tissues. Those concerns remain on the FDA page even though the compounding nomination was withdrawn.
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.
Evidence ledger
LL-37 evidence and regulator ledger
The literature and regulator checks were completed on October 7, 2026. The table puts both human trials beside the regulator record. Laboratory findings, trial observations and compounding-list status answer different questions.
| Record | Design and size | What was reported |
|---|---|---|
| 2014 wound trial | Placebo-controlled, 34 people with venous leg ulcers; mainly safety | No safety concerns recorded in this small study |
| 2021 HEAL LL-37 | Phase IIb, 148 people with venous leg ulcers | No significant healing difference versus placebo in the whole group; subgroup finding called for a new study |
| FDA safety-risk list | Cathelicidin LL-37 appears under nominated but withdrawn, rather than Category 2 | Immune-reaction, impurity and nonclinical safety concerns remain listed; withdrawal is not clearance |
| July 2026 FDA meeting | Seven other substances were on the advisory meeting agenda | LL-37 was not among those substances; that meeting provides no LL-37 clearance |
Sources: Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026; FDA advisory meeting page, July 23 to 24, 2026.
Research timeline
How the LL-37 record was built
Research timeline
How the LL-37 record was built
Research timeline
How the LL-37 record was built
1998: membrane tests
Laboratory work measured bacterial growth, membrane damage and LPS binding.
2000: immune-cell movement
Cell tests linked movement of immune cells toward LL-37 to FPRL1.
2005: vitamin D link
Gene studies found a vitamin D response element in human CAMP.
2007 and 2014: skin research
Separate papers examined cathelicidin in rosacea and LL-37 in psoriasis.
2014: first human trial
A placebo-controlled trial of 34 people with leg ulcers focused on safety.
2021: phase IIb
A trial of 148 people found no significant healing difference in the whole group.
2026: regulator ledger
The FDA listed LL-37 as nominated but withdrawn, with safety concerns still stated.
Sources: Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.
Your Kit
What's Included

$66 USD Was $120 USD
Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp
Black Friday price, 45% off, ends November 30
LL-37 5mg Vial
5mg per vial
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Your Research Order
LL-37 research vial, batch certificate status, delivery and order support.
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Research and citations
Peer-reviewed and regulator sources
- Vandamme et al., 2012, Cell Immunology (PMID 23246832). Review of LL-37 biology, host-cell toxicity and serum interactions.
- Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248). LL-37, the human member of the cathelicidin family.
- Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440). Cathelicidin structure and biological activities.
- UniProt P49913, checked October 7, 2026. Human CAMP precursor and LL-37 sequence.
- PubChem CID 16198951, checked October 7, 2026. LL-37 formula and molecular weight.
- Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536). LL-37 antimicrobial activity, membrane tests and LPS binding.
- De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447). Immune-cell movement through the FPRL1 receptor.
- Gombart et al., 2005, FASEB Journal (PMID 15985530). Vitamin D response element in the CAMP gene.
- Yamasaki et al., 2007, Nature Medicine (PMID 17676051). Cathelicidin patterns in rosacea.
- Lande et al., 2014, Nature Communications (PMID 25470744). LL-37 as a T-cell autoantigen in psoriasis.
- Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740). Placebo-controlled study of 34 people with venous leg ulcers.
- Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253). HEAL LL-37 phase IIb study of 148 people with venous leg ulcers.
- FDA safety-risk list, checked October 7, 2026. LL-37 nomination withdrawn; stated safety concerns remain listed. Page updated April 22, 2026.
- FDA advisory meeting page, July 23 to 24, 2026. Meeting agenda and substances reviewed; LL-37 was not among them.
Explore more
Related guides, comparisons, and compounds studied for related endpoints
Peptide glossary
Plain definitions of peptide and laboratory terms.
Peptide side effects
What published safety research can and cannot establish.
What are peptides
Peptide classes and the difference between research material and medicines.
Are peptides safe
How to read early safety evidence.
Thymosin alpha-1
A separate immune-signaling peptide and its evidence record.
KPV
A three amino acid fragment studied in inflammatory signaling.
ARA-290
An EPO-derived peptide studied in small nerve trials.
Certificates of analysis
Published certificates and pending batch status.
How to verify peptide purity
Identity and purity checks for a research supplier.
FAQ
Buying LL-37: FAQ
Where can LL-37 peptide be bought?
Peptara Labs lists LL-37 as a 5mg research vial on this page. The vial is sold for laboratory research only and its batch certificate remains pending.
How much does LL-37 cost?
One 5mg research vial costs $66 USD, the LL-37 Black Friday price: 45% off the regular $120.
When does LL-37 ship?
Ships as soon as stock arrives. Delivery windows begin after dispatch: 5 to 10 business days.
Is the LL-37 batch certificate available?
The batch certificate of analysis is pending, so no purity figure is claimed yet. Published certificates and pending status are listed on the certificates page. No certificate publication date is promised for this batch.
What comes with an LL-37 order?
One sealed 5mg vial of lyophilized LL-37. Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
LL-37 research FAQ
What is LL-37 peptide?
LL-37 is the only cathelicidin antimicrobial peptide made in the human body. It is 37 amino acids long and comes from the larger hCAP18 protein. Neutrophils and cells lining the skin, airways and gut make its precursor.
What has LL-37 been studied for?
Most of the record is laboratory research on microbes, immune-cell signaling and skin inflammation. Two human trials examined a separate LL-37 product in venous leg ulcers. The larger trial found no significant healing difference from placebo across the whole group.
What side effects have been reported for LL-37?
The small leg ulcer trials recorded no safety concerns during their study windows. Laboratory reviews report that LL-37 can damage host cells at higher concentrations. The FDA lists immune-reaction and impurity concerns, plus animal findings involving male reproduction and tumor growth. Safety over longer periods remains unknown.
Is LL-37 an approved medicine?
No. LL-37 has no medicine approval. Its FDA compounding nomination was withdrawn, which does not clear the listed safety concerns. Peptara Labs sells the vial for laboratory research only.
What does the name LL-37 mean?
LL names the two leucines at the start of its sequence. The number 37 is the number of amino acids in the peptide.
Where does LL-37 come from naturally?
The CAMP gene encodes hCAP18, a larger precursor protein. Enzymes cut LL-37 from that precursor. Neutrophils and epithelial cells make it as part of innate immune biology.
Does vitamin D affect LL-37?
In laboratory research, the active form of vitamin D switched on CAMP through a vitamin D response element in the gene. This describes a gene-level finding.
Is LL-37 the same as an antibiotic?
No. LL-37 is a host-defense peptide that acts on microbial membranes and also signals to immune cells. A standard small-molecule antibiotic is a different kind of compound.
Can LL-37 harm human cells?
Yes. Reviews report damage to host cells at higher concentrations. Laboratory context and concentration affect the findings, and the human safety record remains incomplete.
Is LL-37 linked to any skin conditions?
Research found altered cathelicidin patterns in rosacea and described LL-37 as a T-cell autoantigen in psoriasis. These are findings about disease biology, without evidence for LL-37 as a treatment.
Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440); UniProt P49913, checked October 7, 2026; Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.
Order LL-37, 5mg vial
Order LL-37. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.
Order NowBatch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp